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p53 is an important tumor-suppressor protein that ismutated
inmore than 50%of cancers. Strategies for restoring normal p53
function are complicated by the oncogenic properties ofmutant
p53 and have not met with clinical success. To counteract
mutant p53 activity, a variety of drugs with the potential to
reconvert mutant p53 to an active wildtype form have been
developed. However, these drugs are associated with various
negative effects such as cellular toxicity, nonspecific binding to
other proteins, and inability to induce a wildtype p53 response
in cancer tissue. Here, we report on the effects of a curcumin
analog, HO-3867, on p53 activity in cancer cells from different
origins. We found that HO-3867 covalently binds to mutant p53,
initiates a wildtype p53-like anticancer genetic response, is exclu-
sively cytotoxic toward cancer cells, and exhibits high anticancer
efficacy intumormodels. Inconclusion,HO-3867 isap53mutant–
reactivating drug with high clinical anticancer potential.
p53 is one of the most frequently mutated genes in cancer,
and its loss of activity has been associated with oncogenic pro-
gression inmultiple cancers (1, 2). The p53 transcription factor
regulates oncogenic progression via multiple mechanisms that
involve, but are not restricted to, cell cycle arrest, senescence,
and apoptosis (3–5). Recent discoveries indicate that the tran-
scriptional activity of p53 also determines important biological
processes such as metabolism via regulation of tigar (6–8)
and sco2 (8–10), embryonic development of cardiomyocytes
through Nkx2.5 and troponin T2 (11), and non-cell autono-
mous signaling in the tumor microenvironment (12), suggest-
ing a critical role for p53 in the regulation of basic processes of
human biology. Truncation (13) and transactivation domain
(14), DNA-binding domain (15), and tetramerization domain
mutations in the p53 gene (16) impair the ability of p53 to inter-
act with chromatin (17, 18). This eventually results in the loss of
p53 transcriptional activity toward downstream effector genes
involved in anticancer signaling (2, 13, 19). Loss of p53 activity
via mutations is associated with metastasis and poor prognosis
in breast cancer (20, 21), pancreatic cancer (2, 22), astrocytoma
and oligoastrocytoma (23), and stage 1 non-small-cell lung car-
cinoma (24). Because mutant p53 (p53MT) can accelerate neo-
plastic progression, addressing the in situ mutational status of
p53 may be indispensable for successful anticancer therapy
(2, 3, 25, 26). In conclusion, p53MT promotes aggressive
tumor phenotypes (2, 3), which suggests that the targeting of
p53MT is an important anticancer strategy. Several clinical
trials have been based on strategies to reintroduce wildtype
p53 copies into cancerous tissues (27–29). In addition, there
have been several clinical attempts to use molecular chaper-
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ones that can rescue wildtype p53 (30–33). Because of the
oncogenic role of mutant p53 (3, 26), reactivation of tran-
scriptionally inactive mutant p53 is a promising approach to
cancer therapy (30).
In the past few years, approaches involving drug-assisted
reactivation of p53MT have been adopted to achieve a gain of
p53 function for anticancer effects (34–39). However, an effi-
cient anticancer drug that is both specific for binding p53MT
and nontoxic to normal cells has not been identified. Recently,
mutant p53-reactivating drugs such as PRIMA-1 have been
shown to bind to p53 via SH2 linkage and refold the mutated
forms to transcriptionally active DNA-binding forms to exert
anticancer action (40, 41). A clinical trial with PRIMA-1 under
the name APR-246 has shown an ability to induce changes in
gene expression but with little clinical significance, possibly
owing to the small number of study participants (38). Another
example, RITA, a candidate p53-interacting and -activating
drug (43), was later shown by NMR not to bind to p53 (44).
Chetomin reactivates p53R175H by increasing p53 and Hsp40
interaction (45), although chetomin also has nonspecific p53
effects (46). CP-31398 (47), another putative p53MT-activating
molecule, does not actually bind p53MT but instead interacts
with DNA, destabilizes the DNA–p53 core–domain complex,
and causes nonspecific toxicity in cancer cells (48, 49).
Other small molecules, such as NSC319726, STIMA-1, and
SCH529074 (3), with the potential to restore thewildtype activ-
ity of mutant p53 are in the early stages of development and
testing.
Here we show the potential of a novel curcumin analog
HO-3867 (50) to bind with and reactivate p53MT in cancer cells
and tumor xenografts. HO-3867, a novel diarylidenyl piperi-
done compound and a curcumin analog, has been developed by
incorporating a piperidone link to the-diketone structure and
fluoro-substitutions on the phenyl groups (50). The chemical
design of HO-3867 includes a hydroxylamine group (NOH)
(Fig. S1a), which is converted to a biologically active nitroxide
(NO) form, specifically in the redox-rich environment of
cancer cells (Fig. S1b) (50). Previously, we have shown that
HO-3867 targets other p53-regulated and signaling-related
genes (51). HO-3867 activates p53 (52) and thus effectively
and specifically inhibits the constitutive activation of STAT3
(50), most likely by mechanisms described previously (53).
Another possible p53 downstream effect of HO-3867 has
been observed via the activation of PTEN expression fol-
lowed by the inhibition of Akt activation, cell-cycle arrest,
and apoptosis (52). HO-3867 also has been shown to inhibit
ovarian cancer cell migration and invasion by altering FAS/
FAK expression and by inhibiting vascular endothelial
growth factor signaling in a p53-dependent manner (50).
In the present study, we demonstrated a novel role for
HO-3867 as a p53-activating compound that is exclusively
cytotoxic toward cancer-derived cells. HO-3867 directly
bound to p53MT in vitro, activated the p53 transcriptional
pathway in cancer cells of multiple origins with a broad spec-
trum of p53 DNA-binding domain mutations, and exhibited
anticancer activity in p53MT cancer models.
Results and discussion
Because of concerns regarding toxicity toward healthy (non-
cancerous) cells (38, 39), we developed a clinically derived
model to assess the nonspecific cytotoxicity of HO-3867
toward various human cell types. The cytotoxicity of HO-3867
(10 M) was examined in heterogeneous primary cultures
derived from (i) human breast, colon, and liver normal and
cancer tissues (Fig. 1a); (ii) stromal fibroblasts derived from
breast tissue adjacent to cancer (Fig. 1a); and (iii) chemo- and
radiosensitive tissues such as lymphoid and GI tract (Fig. 1a).
Flow cytometric analysis showed small apoptotic population
uponHO-3867 treatment of cell derived fromnormal tissues or
normal breast fibroblasts or to radiosensitive lymphoid and GI
tract tissues (Fig. 1b). However, HO-3867 exclusively induced
apoptosis in cancer cells of breast, colon, and liver origin (Fig.
1b). Cisplatin was cytotoxic to both normal and cancer cells of
all origins (Fig. 1b). A p53 mutational analysis in the breast,
colon, and liver cancer samples showed the presence of distinct
DNA-binding domain (DBD)4 mutations in each case (Fig. 1c).
The different cancer types harbored unique mutations span-
ning the p53 DBD, and primary cultures were sensitive to
HO-3867–induced cytotoxicity. These data suggest that
HO-3867 acts to halt cancer cell proliferation induced by p53
DBDmutant variants. Also, these data suggest that HO-3867 is
a safe drugwith limited cytotoxicity to normal cellswhile exhib-
iting a high anticancer apoptotic activity. Next, we further
analyzed the p53MT-specific cytotoxicity of HO-3867 (10 M).
Cellular apoptosis was measured in four p53MT (A431, MDA-
MB-468, WRO, and DU-145) and two p53/ (MCF-7 p53/
and HCT p53/) cancer lines. HO-3867 induced significant
apoptosis in p53MT cells, which was reversed by shRNA-medi-
ated p53 knockdown (Fig. 1d, inset). HO-3867was ineffective at
inducing apoptosis in p53/ cells. However, HO-3867
induced significant apoptosis in p53/ cells upon exogenous
addition of p53MT (Fig. 1d). These data suggest that HO-3867
induces cytotoxicity and anticancer activity in a p53MT-depen-
dent manner.
Because HO-3867 induced apoptosis in p53MT cells, we eval-
uated whether there was any direct binding between HO-3867
and p53MT under in vitro conditions. 1H-15N heteronuclear
single-quantum coherence (HSQC) NMR experiments re-
vealed that HO-3867 induces several chemical shift perturba-
tions, especially in close proximity to the solvent-exposed cys-
teine 277 of theDBD (residues 94–312) of p53MTY220C (Fig. 2,
a and b), suggesting a covalent binding mode. A comparison of
the HSQC spectra after 20 or 150 min of incubation with
HO-3867 at room temperature also revealed time-dependent
chemical shift perturbations in the spectra, which is in line with
the putative covalent binding to p53MT Y220C (Fig. 2c). Elec-
trospray ionization (ESI) mass spectrometry experiments
showed amass increase of 713 and 1426Da after incubating the
p53MT-Y220C DBD with HO-3867 for 4 h at room tempera-
4 The abbreviations used are: DBD, DNA-binding domain; HSQC, heteronu-
clear single-quantum coherence; ESI, electrospray ionization; qPCR, quan-
titative real-time PCR; RE, response element; GI, gastrointestinal; FBS, fetal
bovine serum; NMR, nuclearmagnetic resonance; MT,mutant; HRP, horse-
radish peroxidase; ANOVA, analysis of variance.
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ture, confirming covalent modification of p53MT (Fig. 2c).
Additionally, the observed mass increase of 713 Da suggests
that HO-3867 covalently modifies p53 as a dimer. Further
experiments with cysteine to serine mutants (C277S/C182S,
C124S/C182S, andC124S/C277S) of the p53DBD revealed that
the compound specifically reacts with cysteine 182 and cysteine
277 (Fig. 2d). Thus, covalent binding of HO-3867 to p53MT-
Y220C was observed based on structural affinities. We also
expect HO-3867 will bind to and modify other DBD mutant
variants.
After confirming the covalent binding of HO-3867 with
p53MT protein, the p53MT-specific anticancer effects of
HO-3867 (20 mg/kg body weight) were determined in p53WT
(MCF-7), p53MT (A-431), and p53/ (MCF-7 p53p53/) cell
line–induced tumor xenografts (Fig. 3). The top row of Fig. 3a
(control) shows the tumor growth of p53 p53WT, p53MT, and
p53/ untreated xenografts after 28 days; the second row
shows a significant reduction in tumor size when p53WT,
p53MT, and p53/ xenografts were treated with HO-3867
along with exogenous addition of lentiviral particles coding for
p53WT cDNA. No significant effect on tumor growth (size) was
observed upon vehicle treatment (third row) or upon treatment
with lentiviral particles encoding expression of p53 shRNA
(fourth row) (Fig. 3a). p53WT and p53MT tumors treated with
HO-3867 were significantly smaller than the corresponding
untreated tumors (fifth row versus first row, Fig. 3a). The
p53/ tumors did not show similar responsiveness to
HO-3867 treatment (Fig. 3a, fifth row, far right) andwere larger
than the tumors with p53WT and p53MT status (fifth row, left
and center). When the p53WT and p53MT tumors were treated
with HO-3867 along with lentiviral particles coding for p53
shRNA, larger tumors were observed upon p53 silencing (Fig.
3a, sixth row). p53/ cells were treated with HO-3867 along
with lentiviral particles encoding for p53MT cDNA (Fig. 3a, row
6, p53R175H mutant 1, and row 7, p53R273H mutant 2). Interest-
ingly, both p53MT forms along with HO-3867 treatment
resulted in a significant reduction in the volumes of the p53/
tumors (Fig. 3, a and b). It is important to note that HO-3867
treatment reduced the growth of both the p53MT and the
p53null tumors because of the ability of the drug to become
activated in the redox environments of these tumors (Fig. S1),
resulting in reactive oxygen species (ROS)-assisted death of
tumor cells in p53WT and p53null tumors (51–54).
Because NMR data showed that HO-3867 covalently modi-
fied p53MT at its DBD, it was essential to determine whether
such interaction would result in the reactivation of p53-medi-
ated transcription and up-regulation of p53 downstream genes.
We prepared a panel of 29 cell lines carrying various mutations
in the p53 DBD (Fig. 4a). The p53 mutations of each of the 29
p53MT cell lines are shown in Fig. 4a and Fig. S2. A digital
quantitative real-time PCR (qPCR) analysis using the Fluidigm
platform was performed in the 29 p53MT cell lines to evaluate
the expression of 14 genes with well-characterized p53 binding
sites (55) (Figs. S3 and S4). The experiment was performed in
control (untreated), HO-3867–treated (10 M), HO-3867 plus
p53 shRNA–treated, and cisplatin-treated cells (Fig. 4b). The
color blocks (Fig. 4b) are arranged in order of the cell lines listed
(Fig. 4a) by their respective p53 DBD mutations from N-to-C
terminus. The expression of 14 p53-regulated genes was poor
to average in untreated p53MT cells (Fig. 4b, red to yellow color
coding). The expression of these 14 genes was significantly
increased in p53MT cells upon treatment with HO-3867 (Fig.
4b, blue color coding). The HO-3867–induced increase in the
expression of these 14 geneswas reversed upon p53 knockdown
using lentivirus-based shRNA. Cisplatin treatment, which is
used as standard care of therapy, did not activate p53-regulated
genes in p53MT cell lines (Fig. 4b). These data also suggest that
the HO-3867–induced activation of p53-regulated genes in
p53MT lines was a specific biological effect not induced by other
anticancer drugs such as cisplatin. It is important to recognize
that other p53 reactivation drugs can target a specific set of p53
mutations (37–40, 43–45, 47–49); however, the biological
activity of HO-3867 appeared to reactivate the transcriptional
response of cells with an especially wide variety of p53 muta-
tions as noted in (Figs. 4a and S2).
Because HO-3867 treatment resulted in increased expres-
sion of p53-regulated genes in p53MT cells, we investigated
whether this effect was associated with a direct interaction
between p53MT and p53-DBD at the promoter of the target
genes. To further evaluate this possibility in a genetically trac-
table model, we conducted ChIP analysis in HO-3867–treated
(10 M) p53MT (A-431) and p53/ (MCF-7 p53/) cancer
Figure1.HO-3867exhibitsdifferential cytotoxicity to cancer cellswithp53MT comparedwithhealthy (noncancerous) cells.a, clinically relevantmodels
were used to analyze the safety of HO-3867 toward normal body cells while simultaneously observing its anticancer efficiency in human cancer-derived cell
populations. The graphical representation shows the isolation of heterogeneous cell populations from breast, colon, and liver cancer samples. In addition,
noncancerous healthy cells such as fibroblasts from stromal tissue adjacent to breast cancer and radio- and chemosensitive cells from lymphoid and GI tract
tissue were used. All of these cells were treated with HO-3867, cisplatin, or vehicle alone. b, a cancer-specific pro-apoptotic effect of HO-3867 was observed in
all cells depicted in panel a. Cells were treated with HO-3867 (10M), cisplatin (10M), or vehicle (DMSO) alone, and apoptosis wasmeasured using annexin V
flow cytometry. HO-3867 selectively induced apoptosis in tumor-derived cells andminimal apoptosis in primary culture fromnormal tissue of different origins
as well as tumor-adjacent stroma-derived fibroblasts and radiosensitive lymphoid and GI tract tissue. Cisplatin nonspecifically killed a significantly higher
percentage of cells derived from normal tissues (n 3 for all experiments; p values are as indicated, ANOVA was used for p value calculations, and error bars
indicate standard deviation). c, p53mutational analysis of breast, colon, and liver cancer samples used for the cell cultures shown in b confirms the presence of
DNA-binding domain mutations. The exact nucleotide sequence point mutations and resulting amino acid sequence changes are depicted. d, the ability of
HO-3867 to induceapoptosis in cancer cellswith ap53MTgenotypewasdeterminedusingannexinV flowcytometry.p53MT cells (A431,MDA-MB-468,WRO, and
DU-145) and p53/ cells (MCF-7p53/ and HCT7p53/) were used in the analysis. Cellular apoptosis was not observed in untreated p53MT and p53/ cells
(bars 1–6). shRNA-mediated p53 knockdown and the exogenous addition of p53MT cDNA were used as controls in untreated cells (bars 7–18). In the experi-
mental set, all cell lines were treated with HO-3867, and p53MT cells showed a significant increase in cellular apoptosis (bars 19–22). HO-3867–treated p53null
cells didnot showamarked increase in apoptosis (bars 23–24). shRNA-mediatedp53MT knockdownabolished theHO-3867–induced increase in apoptosis (bars
25–30). Theexogenousadditionofp53MT cDNAalongsideHO-3867 treatment significantly increasedapoptosis inbothp53MTandp53/ cells (bars 31–36) (n
3; mean S.D. shown). p values are shown on the figure; standard ANOVA test). Inset, the efficiency of lentiviral particles coding for p53MT cDNA or p53 shRNA
was demonstrated using immunoblotting of MCF-7 p53/ or MCF-7 cells. Untreated MCF-7 p53/ samples showed no expression of p53 (lane 1). Overex-
pression of increasing amounts of p53MT cDNA led to increased p53 protein levels. p53 shRNA treatment showed effective knockdown of p53 expression (a
representative image from n 3 replicates is shown).
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cells to assess the interaction of p53 with response elements
(RE) of its critical apoptosis and cell-cycle regulatory genesBAX
and CIP1 (p21 gene), respectively (Fig. 4c). HO-3867 treatment
resulted in a significant increase in p53–RE interaction in
p53MT cells, which was reversed upon p53 silencing. Further,
no p53–RE interaction was observed in p53/ cells. However,
the restoration of p53–RE interaction was observed in
HO-3867–treated p53/ cells exogenously expressing p53MT,
suggesting that HO-3867 can directly restore the binding of
p53MT chromatin interaction. The results were further corrob-
orated at the protein level by performing a Western blotting
for two crucial p53 downstream targets, p21 and NOXA (Fig.
4d). p53WT (MCF-7), p53MT (A-431), and p53/ (MCF-7
p53p53/) cancer cells were used for the study.HO-3867 treat-
ment resulted in an increase in protein expression in both
p53WT andp53MT cancer cells (Fig. 4d, lanes 4 and 5) compared
with untreated control cells (lanes 1–3). Further, the treatment
showed no effect on the p53/ cancer cells (Fig. 4d, lane 6). A
significant increase in NOXA and p21 expression was observed
in HO-3867–treated p53/ cells, exogenously expressing
p53MT cDNA (Fig. 4d, lane 8) comparedwith untreated p53/
cells exogenously expressing p53MT cDNA alone (lane 7).
These findings substantiate the role of HO-3867 in the restora-
tion of p53WT transcriptional activity.
Next, we sought to identify the mechanistic changes that
enable p53MT to interact with chromatin in the presence of
HO-3867. The p53 conformation-specific antibodies (Ab) 1620
and 240 were used to specifically detect cellular p53WT and
p53MT forms, respectively (56). Immunoprecipitation assays
using Ab 1620 and Ab 240 with lysates from A-431 (p53MT),
MCF-7 (p53WT), and MCF-7 p53/ tumors were performed
to determine whether HO-3867 induces a p53MT to p53WT
conformational change in p53MT tumors and cell lines (Fig. 5a).
In untreated MCF-7 tumors, p53 was recognized by Ab 1620
(lane 3), and a small fraction of cellular p53 was also recognized
by Ab 240. This observation is consistent with previous studies,
as some fraction of p53 in wildtype cells or tissues exists in a
misfolded/unfolded form, which is recognized by the p53MT-
specific Ab 240 (32, 56). In untreated A-431 tumors, p53 was
recognized by Ab 240 (Fig. 5a, lane 4). However, HO-3867-
treatment (20 mg/kg) of A-431 tumors resulted in the conver-
sion of p53 conformation from anAb 240–recognized to an Ab
1620–recognized form (Fig. 5a, compare lane 4 with lane 11).
The exogenous addition of p53MT cDNA in HO-3867–treated
A-431, MCF-7, and MCF-7 p53/ tumors showed a strong
presence of p53 in a wildtype form recognized by Ab 1620 (Fig.
5a, compare lanes 9 and 10with lanes 17 and 18). Similar exper-
iments using Ab 1620 and Ab 240 were repeated in MCF-7,
HCT (p53WT), A-431, DU-145, MDA-MB-231 (p53MT), and
MCF-7 p53/, HCT p53/ cell lines (Fig. 5b). In untreated
p53MT cells, p53MT existed exclusively in a mutant form recog-
nized by Ab 240 (Fig. 5b, rows 5–7, lane 4). Upon HO-3867
treatment (10M) of p53MT cells, p53MT is converted to a wild-
type form recognized by 1620 Ab (compare conversion from
240 to 1620 form) (Fig. 5b, lanes 4 and 5). Together, these data
suggest that HO-3867 treatment in p53MT xenografts and cell
lines converted p53 from amutant to a wildtype conformation.
Using an in vitro cell-free transcription assay with a synthetic
DNA template, we further analyzed whether the HO-3867–
induced change in p53MT conformation to the wildtype form
would also result in the activation of p53MT-dependent tran-
scription. The DNA template pWAFMLT consisted of a
poly(6)-p53 DNA-binding site (p21-DBS) followed by an ade-
novirus major late core promoter (AdMLT), a transcription
start site, a G-less cassette as the coding region, and a poly(A)
tail coding region (for qPCR-based detection) followed by a
CCT stop signal respective to the G-less cassette (57) (Fig. 5c,
top). The in vitro transcription assay was designed where
nuclear extracts from p53/H1299 cells were the only source
of RNA polymerase machinery. p53 immunoprecipitated from
HO-3867–treated (10 M) and untreated MCF-7 (p53WT),
A-431, T47D, MDA-MB-468, and DU-145 cell lines was used
to observe p53MT-dependent in vitro transcription. p53 im-
munoprecipitated from HO-3867–treated cells significantly
increased in vitro transcript synthesis when incubated with
H1299 nuclear extracts (Fig. 5c, bottom). These results were
further confirmed via a luciferase-based reporter transcription
assay under in vivo conditions using the same set of p53MT,
p53WT, and p53/ cell lines. In accordance with the in vitro
transcription assay, the luciferase assay showed HO-3867–
induced transcription by p53MT in multiple cell types (Fig. 5d).
These results document the ability of HO-3867 to modulate
p53MT activity by changing its conformation and directly
restoring p53 transcriptional activity.
p53 is one of the most frequently mutated genes in cancer,
and p53MT promotes aggressive oncogenic phenotypes. Thus,
restoration of p53WT function is actively being explored as an
anticancer strategy and p53 reactivation drugs have an impor-
tant role. Clinical use of this class of drugs has been precluded
because of their non-specificity and cytotoxicity. In this study,
we demonstrated the anticancer properties of HO-3867, which
induced apoptosis in cancer cells with minimal toxicity to
normal cells. Mechanistically, HO-3867 covalently bound to
mutant p53 and restored its wildtype conformation, transcrip-
tional activity, and anticancer function. Gain of wildtype-like
p53 function uponHO-3867 treatment effectively blocked can-
cer growth in mouse models, irrespective of p53 mutational
status. Importantly, HO-3867 restored thewildtype activity of a
variety of p53 DBDmutants, which makes it a suitable drug for
targeting cancers with complex p53 mutational status. Taken
Figure 2. HO-3867 covalently binds to p53MT in the DNA-binding domain. a, 1H-15N HSQC NMR spectrum of the p53MT-Y220C core domain (75 M) after
incubation with (green) or without (red) 1000 M HO-3867 for 70 min. Chemical shift perturbations were observed for residues in proximity to the solvent-
exposed cysteine 277. b, an NMR-generatedmodel depicting the putative sites of interaction between p53MT and HO-3867. c, 1H-15N-HSQC NMR spectrum of
the p53MT-Y220C core domain (75 M) after incubating with (green) or without (red) 430 M HO-3867 for 20 or 150 min. Chemical shift perturbations were
time-dependent, suggesting a covalent bindingmode.d, ESI (ES)mass spectra of thep53MT-Y220Ccoredomain (50M) after incubationwithout (left) orwith
HO-3867 (right) for 4 h at room temperature. HO-3867 treatment led to amass increase of 713 or 1426Da, confirming covalent binding to the p53 core domain
by HO-3867. e, ESI (ES) mass spectra of p53 DBD (50 M) C182S/C277S, C124S/C277S, and C124S/C182S mutants after incubation without (left) or with
HO-3867 (right) for 4 h at room temperature. HO-3867 treatment led to a mass increase of 713 Da only for the C124S/C277S and C124S/C182S mutants,
confirming selective covalent modification of Cys-277 and Cys-182 by HO-3867.
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together these results highlight the potential of HO-3867 as a
safe, specific, and effective anticancer drug.
Experimental procedures
Cell lines and culture conditions
p53MT cells (HEC-1-A, CCRF-CEM, KLE, T47D, SW837,
MDA-MB-468, SK-UT-1, SK-LMS-1, SKLU1, Calu-6, SNU-16,
DMS-53, SW1271, BT-20, BT-549, MDA-MB-231, BT-474,
HOS, DLD-1, MOLT-4, WiDr, PSN-1, MC116, ST486,
P3HR-1, NCI-H23, HT-3, NCI-H1882,WRO, HCT-15, A-431,
andDU-145), p53WT (MCF-7 andHCT116), and 293T cells (for
lentiviral production) were procured from ATCC (Manassas,
VA). p53/ cells were derived from p53WT (MCF-7 and
HCT116) as described previously (9). Normal breast fibroblasts
were isolated at Barts Cancer Institute, QueenMary University
of London, using surgically resected breast tissue with Dulbec-
co’smodified Eagle’smedium (DMEM)/F12 10% fetal bovine
serum (FBS), penicillin/streptomycin, and 2.5 g/ml Fungi-
zone. Tumor cell populations from breast, colon, and liver can-
cer tissue and normal cells from lymphoid and GI tract tissue
were extracted using human tissuematerial provided byUnited
Kingdom-based Tissue for Research, as described previously
(58). Briefly, the cells were cultured in monolayer in respective
growth media (DMEM or RPMI 1640) supplemented with 10%
(v/v) heat-inactivated FBS and antibiotics (1% penicillin/strep-
tomycin) and incubated at 37 °C in a humidified atmosphere of
95% air and 5% CO2.
NMR
1H-15NHSQC sample spectrawere recorded and analyzed as
described (59). Briefly, samples containing uniformly 15N-la-
beled T-p53C-Y220C (75 M) and 0.43 or 1 mMHO-3867 were
measured at 293 K on a Bruker Avance-800 spectrometer using
a 5-mm inverse cryogenic probe after 20, 70, or 150 min of
incubation at room temperature. Spectral analysis was per-
formed using Sparky 3.11430 and Bruker Topspin 2.0 software.
A previously described assignmentmap of the p53-Y220CDBD
was used to label residues (60).
Mass spectrometry
Samples containing 50 M T-p53C-Y220C (residues 94-
312) or 50 M T-p53C (residues 94–312) cysteine to serine
mutants (C277S/C182S, C277S/C124S, and C182S/C124S), 25
mM potassium phosphate, pH 7.2, 150 mM sodium chloride, 1
mM tris(2-carboxyethyl)phosphine, and 5% DMSO were pre-
pared with or without 2 mM HO-3867 and incubated for 4 h at
20 °C. The sampleswere then diluted to 5Mprotein in 100mM
ammonium acetate buffer and desalted usingMillipore C4 Zip-
Tips. Protein mass was determined via electrospray mass spec-
trometry with a Waters (Milford, MA) Micromass LCT TOF
mass spectrometer in ESI (ES) mode.
Digital droplet qPCR
Digital droplet qPCR was performed at the University of
Nebraska DNA Sequencing Core (Omaha, NE). Reverse tran-
scription, preamplification, and qPCR were performed accord-
ing to the manufacturer’s protocols (Fluidigm, San Francisco,
CA). cDNA preparation was performed with 100 ng of RNA
using Fluidigm RT master mix. Reverse transcription was fol-
lowed by 10 preamplification cycles, cleanup with Exonuclease
I (Fluidigm), and then a 10-fold dilution. qPCR was performed
for 30 cycles.
Chemicals, kits, and plasmids
DMEM,RPMI, penicillin, streptomycin, FBS, trypsin-EDTA,
PBS, TRIzol reagent, Lipofectamine 2000 transfection reagent,
Dynabeads-protein A, the SuperScript VILOTM cDNA syn-
thesis kit, and other chemicals of culture grade were purchased
from Life Technologies. Dichlorofluorescin diacetate and
DMSO were procured from Sigma. Protein G PLUS-agarose
was procured from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Calibrated pipettes used for EPR were procured from
VWR International. An annexin V FITC detection kit and a 1:1
mixture ofMatrigel were obtained fromBDBiosciences. ACig-
nal p53 Reporter (luciferase) kit was purchased from Qiagen.
Anti-rabbit p53 (FL-393) polyclonal antibodies; anti-mouse
p53 WT conformation 1620 and p53 MT conformation 240
monoclonal antibodies; and goat anti-rabbit IgG-HRP and
anti-mouse IgG-HRP secondary antibodies (Santa Cruz Bio-
technology) were used. p53WT, p53MT R175H, p53MT R273H,
and p53MT Y220C plasmidswere procured fromAddgene (Cam-
bridge, MA).
Figure3.HO-3867showsanticancerefficacy inbothp53MTandp53WT tumorxenograftsby inducingp53MT–RE interactionand inducesexpressionof
p53downstreameffectors. a, the anticancer effect of HO-3867 on genetically tractable tumor xenografts of p53WT (MCF-7), p53MT (A-431), and p53/ (MCF7
p53/) cells was observed (n 3). In row 1, the excised tumors for untreated p53WT, p53MT, and p53/ xenografts after 4 weeks are shown. In row 2, all of the
tumors were treatedwith HO-3867 alongwith lentivirus-assisted overexpression of p53WT. A reduction in the tumor volumes of all tumor types was observed
in row 2 when compared with the control (row 1). In row 3, tumors were treated with vehicle (DMSO) and lentiviral transfections. The tumor volumes in the
vehicle-treated group remained unaltered. In row 4, all tumors were treated with lentivirus coding for p53 shRNA. In row 5, all tumors were treated with
HO-3867, and p53WT tumors and p53MT tumors showed a decrease in tumor volume for all biological replicates. Interestingly, in p53 knockdown tumors,
HO-3867 did not exhibit very high anticancer efficacy. These data suggest a role for p53 in HO-3867-mediated anticancer activity that appears to be indepen-
dent of p53 mutational status. In row 6, p53WT and p53MT tumors were treated with HO-3867 along with lentiviral particles coding for p53 shRNA. p53
knockdown in these tumors reversed the anticancer effect ofHO-3867, andall biological replicates inboth experimental groups showed larger tumor volumes.
In rows 6 and 7, p53 null tumor xenografts were treated with HO-3867 and lentiviral particles coding for p53MT cDNA (p53R175H (row 6); p53R273H (row 7)).
Interestingly, HO-3867 reduced tumor growth in the presence of p53MT cDNA (compare tumor volumes in row 5with rows 6 and 7) (n 3) (HO-3867 treatment
started at week 0 in the plot). b, tumor growth curves showing the volume of MCF-7 p53WT, A-431 p53MT, and MCF-7 p53/ tumors in the eight treatment
groups over the course of 4 weeks. In both MCF-7 p53WT and A-431 p53MT tumors, treatment with HO-3867 and HO-3867 p53WT cDNA led to the greatest
reduction in tumor volume. Treatment of MCF-7 p53/ tumors with HO-3867, HO-3867p53R175H cDNA, and HO-3867p53R273H cDNA led to a signifi-
cant reduction in tumor volume comparedwith control. In the insets, the efficiency of lentiviral particles coding forp53 shRNA,p53WT cDNA, orp53MT cDNAwas
demonstrated in MCF-7 p53WT or A-431 p53MT cells using immunoblotting with the indicated antibodies. MCF-7 p53WT and A-431 p53MT samples treated with
p53 shRNA showed no expression of p53 (lane 2). p53 shRNA showed effective knockdown of p53 expression. MCF-7 p53/ cells were treated with p53WT,
p53R175H, and p53R273H cDNA and blottedwith anti-p53 antibody or anti-GAPDH antibody (loading control). Overexpression of p53WT cDNA or p53MT cDNA led
to increased p53 protein expression in MCF-7 p53/ cells (HO-3867 treatment started at week 0 in the plot. n 3 for all experiments; p values are labeled on
the figure, and two-factor ANOVA with repeated measures was performed for p value calculations).
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Figure 4. HO-3867 converts mutant p53 conformation to its wildtype form. a, model depicting sites of mutagenesis in the p53 gene in a panel of 29 cell
lines. All mutations are present in the p53DNA-binding domain. b, a Fluidigm digital qPCR-based gene expression analysis of a panel of 14 genes (Fig. S3) was
conducted in a panel of 29 control and HO-3867–treated cell lines. Consistent with qChIP analysis, p53-regulated genes were overexpressed in all HO-3867–
treated p53MT cell lines; this effect was reversed upon p53 shRNA treatment. Cisplatin (10 M) was used as a positive control for p53 activation. (n 5 for all
experiments; p values are labeled on the figure, and ANOVAwas performed for p value calculations). c, ChIP analysis was conducted in a genetically tractable
system of p53MT (A-431) and p53/ (MCF-7p53/) cell lines to measure the binding of p53MT to its REs at the bax (left) and p21 (right) promoters. The results
wereanalyzedusing theQIAxcel advanced instrumentplatform (Qiagen). Input (lane1), noantibody (lane2), actin antibody (lane3), andp53 shRNA (lanes 5and
11) were used as controls. The data show the presence of p53 on the bax and p21promoters in HO-3867–treated p53WT and p53MT cell lines but not p53/ cell
lines (lane 8). Exogenous additionof eitherp53WT (lane 12) orp53MT (lane 13) cDNA resulted in significantbindingofp53at its respectiveREs inHO-3867–treated
p53MT and p53/ cell lines. d, up-regulation of two important p53 target genes, p21 and Noxa, was confirmed at the protein level by Western blotting. A
genetically tractable system of p53WT (MCF-7), p53MT (A-431), and p53/ (MCF-7 p53/) cells was used to study the effect of HO-3867 treatment (10 M) in
p53MT cells (lanes 1–6). Lane 7, both p21 and Noxa Western blotting show less expression in MCF-7 p53/ cells transfected with p53MT cDNA. However, the
same combination in the presence of HO-3867 significantly increases p21 and Noxa expression (lane 8).
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Protein expression and purification
The stabilized DNA-binding domain (residues 94–312) of
the p53 mutant Y220C (T-p53C-Y220C) and T-p53C cysteine
mutants (C124S/C277S, C124S/C182S, and C182S/C277S)
were expressed and purified as described (60).
Treatment with HO-3867
All stock solutions for HO-3867 were freshly prepared in
DMSO. HO-3867 (molecular mass, 713 Da) was synthesized
and purified as described previously (49–51). For cell line–
based studies, a dose of 10M concentrationwas used for treat-
ment. For animal studies, mice were administered with
HO-3867 (20 mg/kg body weight) in 0.2 ml intravenously.
Injections were performed once daily for the first 7 days of
treatment followed by one injection (20 mg/kg body weight)
every 8 days until the end of the treatment schedule.
Gene silencing and overexpression using lentiviral
transduction
All work with lentiviruses was performed under BL2/BSL-2
conditions. Lentiviral particles were produced in 293T cells
plated in a 96-well plate (20,000 cells/well) and supplemented
with 10% fetal bovine serum and 4mM L-glutamine 24 h prior to
infection. For the knockdownof bothWTandMT p53, the cells
were co-transfected with a combination of five different MIS-
SION p53 shRNA particles (SHCLNG-NM_000546) (Sigma)
along with a MISSION lentiviral packaging mix (Sigma) using
Lipofectamine 2000 reagent (Sigma). For the overexpression of
WT p53 cDNA or MT p53 cDNA, the ViraSafeTM (Pantropic)
lentiviral packaging system (Cell Biolabs, San Diego, CA) was
used to generate lentiviruses. The supernatant was collected
starting at 24–72 h post-transfection, pooled, and filtered
through a 0.45-m filter. The virus particles were concentrated
by ultracentrifugation, and the physical titer of virus particles
was determined as per the manufacturer’s protocol. For animal
studies, lentiviral transduction of tumors in vivo was achieved
in established cell line (A-431, MCF-7, and MCF-7 (p53/))
xenografts. Briefly, once tumor sizes reached 1–1.5 cm3, mice
were anesthetizedwith 1.5–3% isofluranewith 30%oxygen, and
in vivo transduction of the lentivirus was achieved through
intratumoral injections of the desired lentivirus. Lentiviral
supernatant was thawed at 37 °C and diluted in 0.9% saline
(injection, USP) and Polybrene (4g/ml final concentration) to
give a dose of 1.6  108 transduction units (TU) in a 50-l
volume/injection (intratumoral).Multiple injections per tumor
were given to cover the spread of the lentivirus throughout the
tumor volume. The respective lentiviral injections were given
twice daily for the first 4 days of the treatment followed by once
every 3 days until the end of the treatment. The viral superna-
tants were mixed with Lipofectamine 2000 (5% final v/v, Invit-
rogen) 30 min before the instillation to increase the transduc-
tion efficiency.
Cancer xenografts
Female athymic nu/nu mice were housed in laminar flow
cabinets under specific pathogen-free conditions and used at
4–5months of age. All animalswere usedwhen between 20–22
g in weight and were purchased from Taconic Biosciences.
Food andwaterwere available ad libitum for the duration of the
studies. All animal protocols were approved by the Institutional
Animal Care and Use Committee at Dartmouth College. The
cell line xenografts were established as described previously (9,
11, 32). Briefly, the desired cell lines (A-431, MCF-7 (p53/)
andMCF-7 (p53/)) were maintained in DMEM/F12 supple-
mented with 10% FBS and 1% antibiotics. For injection, cells at
70–90% confluency were trypsinized and resuspended in
serum-free media with 1:1 Matrigel at a concentration of 1 
107 cells/ml on ice. Cell viability, required to be at least95%,
was determined by a trypan blue exclusion assay. For tumor
induction, animals were first anesthetized with 1.5–3% isoflu-
rane with 30% oxygen. An 80-l cell suspension containing 1
107 cells was subcutaneously injected in the left or right mam-
mary gland of mice. The vehicle control used for the study was
DMSO. Tumor volumesmonitored weekly by calipermeasure-
Figure 5. HO-3867 converts mutant p53 conformation to its wildtype form. a, the p53MT and p53WT forms were immunoprecipitated using Ab 240 or Ab
1620, respectively, and immunoblotted using a polyclonal anti-p53 antibody (FL393) in p53MT (A-431), p53WT (MCF-7), andMCF-7p53/ tumors. Input (lane 1),
actin antibody (lane 2), and p53 shRNA (lanes 5 and 6) were used as controls for all tumors. In untreatedMCF-7 tumors, p53was recognized by Ab 1620 (lane 3)
and to aminor extent by Ab 240 (lane 4). In untreated A-431 tumors, p53was exclusively recognized by Ab 240 (lane 4). No signal was detected inMCF-7p53/
tumors (third row). Overexpressionofp53WT andp53MT cDNA in all three tumors resulted in a strong signal forAb1620 (lane 7) andAb240 (lane 10), respectively.
HO-3867 treatment inMCF-7 tumors significantly increased detection by Ab 1620 (compare lanes 3with 11). HO-3867 treatment in A-431 tumors resulted in a
change in the p53 conformation from an Ab 1620–recognized form to an Ab 1620–recognized form (compare lanes 4 and 11). HO-3867 had no effect on
MCF-7p53/ tumors. Exogenous addition of p53WT cDNA in HO-3867–treated A-431, MCF-7, and MCF-7p53/ tumors showed the strong presence of p53 in
theAb1620–recognized form (lanes 15 and 16). Exogenous addition ofp53MT cDNA inHO-3867–treatedA-431,MCF-7, andMCF-7p53/ tumors again showed
the strong presence of p53 in the Ab 1620–recognized form (lanes 17 and 18) (n 3). b, wildtype andmutant forms of p53were immunoprecipitated using Ab
1620 and Ab 240, respectively, and immunoblotted for p53 protein (FL393) in p53WT (MCF-7 and HCT) or p53MT (A-431, DU-145, and MDA-MB-231) cell lines.
Input (lane 1) and actin antibody (lane 2) were used as controls. In untreated p53WT cells, p53 was recognized by Ab 1620 (lane 3, rows 1 and 3). p53/
(MCF-7p53/ and HCTp53/) cells served as negative controls and showed no p53 signal (rows 2 and 4). In untreated p53MT cells, p53 existed exclusively in an
Ab240–recognized form (lane 4, rows 5–7), which uponHO-3867 treatment converted to anAb1620–recognized form (compare conversion from240 to 1620
form, lanes 4 and 5) (n3). c, graphical representationof the experimental design for conducting in vitro transcription assays (top). The syntheticDNA template
consisted of a poly(6)-p53 DNA-binding site followed by an adenovirus major late core promoter, a transcription start site, a G-less cassette as the coding
region, and a poly(A) tail coding region (for qPCR-based detection) followed by a CCT stop signal. Nuclear extracts from p53null (H1299) cells were the source
of the RNA polymerase machinery. Lack of reverse transcriptase to convert synthetic transcripts to a qPCR-detectable form in the reaction mix served as a
negative control (NoRT,bars 1and7). p53 immunoprecipitated fromuntreatedMCF-7 cells in combinationwithH1299nuclear extracts showedbasal transcript
synthesis (second bar). p53 from p53MT cell lines in combination with H1299 nuclear extract resulted in minimal transcript synthesis (bars 3–6). p53 immuno-
precipitated from HO-3867–treated p53WT and p53MT cell lines in combination with H1299 nuclear extracts successfully generated RNA transcripts from the
synthetic DNA template (blue) (n 3 for all experiments; p values are labeled on the figure, and ANOVAwas performed for p value calculations). d, luciferase-
based reporter transcription assay (Cignal) was used to analyze p53-dependent transcription in HO-3867–treated p53MT cell lines in vivo. Empty vector (bars 1
and 7) was used as a negative control. Standard p53-dependent transcription was observed in p53WT MCF-7 cells. Results showed minimal p53-dependent
transcription in a variety of p53MT cell lines. The effect of HO-3867 on p53-induced transcription was observed in treated p53WT and p53MT cells (n 3 for all
experiments; p values are labeled on the figure, and ANOVA was performed for p value calculations).
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ment of the length, width, and height were calculated using the
formula for a semi-ellipsoid ((L*L*W)/2). After 3 weeks, mice
bearing tumors with volumes averaging0.0015 cm3were ran-
domized for treatments in different groups (3 mice/group).
Annexin V flow cytometry
A Becton Dickinson flow cytometer (BD-LSR II, BD Biosci-
ences) was used to detect the apoptotic cell surface shift of
phosphatidylserine by the binding of FITC-conjugated annexin
V to the outer membrane of intact cells. The attached cells
(untreated and treated (24 h)) were gently scraped off the dish,
centrifuged (500  g for 5 min), and washed in PBS (Ca2- or
Mg2-free), 0.1% EDTA. The pelleted cells were treated with
500l of binding buffer followed by 5l of FITC, and then 5l
of propidium iodide (10 g ml1) was added. Cells were incu-
bated at room temperature for 5 min. These cells were then
filtered (70-m mesh) to eliminate cell aggregates and ana-
lyzed by flow cytometry.
Luciferase assay
To study the effect of HO-3867 on transcription by p53MT,
the p53MT cells were plated in 35-mm Petri dishes the day
before transfection so that they could reach 60–80% conflu-
ency upon transfection. Reporter plasmids (1.0–1.5 mg/well)
were transfected with Lipofectamine 2000 reagent as per the
manufacturer’s instructions. After the desired incubation
period, the cells (untreated and treated (24 h)) were washed in
cold PBS three times and lysed with 200l of the lysis buffer by
a freeze-thaw cycle, and the lysates were collected by centrifu-
gation at 14,000 rpm for 2min in a benchtop centrifuge. 20l of
supernatant was used for the assay of luciferase activity using
a Cignal p53 Reporter (luc) kit as per the manufacturer’s
instructions.
Chromatin immunoprecipitation
The ChIP experiments were performed essentially as
described previously (9, 31, 61, 62). An anti-p53 (FL-393) rabbit
polyclonal antibody was used for the study. Formaldehyde was
added at a final concentration of 1% directly to the cell culture
media. Fixation proceeded at 22 °C for 10 min and was stopped
by the addition of glycine to a final concentration of 0.125 M.
The cells (untreated and treated (24 h)) were collected by cen-
trifugation and rinsed in cold phosphate-buffered saline. The
cell pellets were resuspended in swelling buffer (10 mM potas-
sium acetate, 15 mMmagnesium acetate, 0.1 M Tris, pH 7.6, 0.5
mMphenylmethylsulfonyl fluoride, and 100 ng of leupeptin and
protinin/ml), incubated on ice for 20 min, and then Dounce-
homogenized. The nuclei were collected by microcentrifuga-
tion and then resuspended in sonication buffer (1% SDS, 10mM
EDTA, 50 mM Tris-HCl, pH 8.1, 0.5 mM phenylmethylsulfonyl
fluoride, and 100 ng of leupeptin and aprotinin/ml) and incu-
bated on ice for 10 min. Prior to sonication, 0.1 g of glass beads
(212- to 300-mm diameter, Sigma) was added to each sample.
The samples were sonicated on ice with an Ultrasonics sonica-
tor at setting 10 for six 20-s pulses to an average length of
1,000 bp and thenmicrocentrifuged. The chromatin solution
was precleared with the addition of Staphylococcus aureus pro-
tein A–positive cells. Prior to the first wash, 20% of the super-
natant from the reaction with no primary antibody for each
time point was saved as total input chromatin and was pro-
cessed with the eluted immunoprecipitates beginning at the
cross-link reversal step. Cross-links were reversed by the addi-
tion of NaCl to a final concentration of 200 mM, and RNA was
removed by the addition of 10 mg of RNase A/sample followed
by incubation at 65 °C for 4–5 h. The samples were then pre-
cipitated at 20 °C overnight by the addition of 2.5 volumes of
ethanol and then pelleted by microcentrifugation. The samples
were resuspended in 100 ml of Tris-EDTA, pH 7.5, 25 ml of
proteinase K buffer (1.25% SDS, 50mMTris, pH 7.5, and 25mM
EDTA), and 1.5ml of proteinaseK (RocheApplied Science) and
incubated at 45 °C for 2 h. After digestion with proteinase K,
samples were extracted with phenol-chloroform-isoamyl alco-
hol (25:24:1) and then precipitated with 1/10 volume of 3 M
sodium acetate NaOAc, pH 5.3, 5 mg of glycogen, and 2.5 vol-
umes of ethanol. The pelleted chromatin was collected by
microcentrifugation, resuspended in 30 l of water, and ana-
lyzed by PCR and qPCR to study p53–RE interaction at the
promoter of bax or p21 genes. The primers used for ChIP anal-
ysis are as described previously (55).
The samples were run on the QIAxcel Advanced instrument
(Qiagen) using aQIAxcelDNAhigh resolution kit (Qiagen) and
the 0M500 method (sample injection voltage of 5 kV and sepa-
ration voltage of 5 kV) with a sample injection time of 15 s.
During the run we used the QX DNA Size Marker, 25–500 bp,
version 2.0, and the corresponding QX Alignment Marker,
15/600 bp (Qiagen). To analyze the results, we used QIAxcel
ScreenGel software. Sample analyses were performed using a
two-step approach. First, peaks were detected in the raw data.
In a second step, the peak sizes and peak concentrations were
determined by mapping the detected peaks to the peaks of the
reference size marker.
Reverse-transcriptase real-time PCR
Using the TRIzol method, RNAwas extracted from cells and
tumor grafts following transfections with respective cDNAs
and treatment with HO-3867 (24 h). cDNAs were synthesized
from 2.5 g of RNA in a 20-l volume using the SuperScript
VILO cDNA synthesis kit (Thermo Fisher Scientific) according
to the manufacturer’s protocol. qPCR was performed using
384-well plates in a final volume of 20l onQuantStudio 6 Flex
(Applied Biosystems, Life Technologies). TaqMan Universal
Master Mix II (Applied Biosystems) was used to perform the
reaction together with primers (for studying the expression of
p53-regulated downstream genes) purchased from Invitro-
gen (Life Technologies). Relative mRNA quantification was
obtained using the comparative Ct method (		Ct), where
GAPDH and -actin genes served as internal controls.
In vitro transcription
In vitro transcription reactionswere carried out essentially as
described previously (42, 57) using 50 ng of G-less DNA tem-
plates. H1299 nuclear extracts along with purified p53 from the
desired cell lines (by two rounds of immunoprecipitation) and
template DNA were preincubated at room temperature for 10
min before nucleotides were added to the mixture. Reaction
mixtures (20l) contained 2.5mMNaF, 0.5 mM orthovanadate,
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10 mM HEPES (pH 7.9), 12 mM Tris (pH 8.0), 0.1 mM EDTA,
12% glycerol, 60 mM KCl, 5 mM MgCl2, 0.5 mM ATP, 0.5 mM
UTP, 20MCTP, 0.25mMO-methyl-GTP, 5mMcreatine phos-
phate, and 10 M HO-3867. The DNA template contains six
p53 DNA binding sites at the p21/WAF gene promoter
upstream of the AdML (adenovirus major late) core promoter
(57), a transcription initiation signal attached to a G-less cas-
sette (which gives rise to transcripts of 440 nucleotides), a
poly(A) signal, and finally a stop signal (CCT). Quantitative
detection of the transcripts was done by converting the tran-
script to a cDNA form using poly(T) primers followed by qPCR
using extension primers.
Immunoblotting
Tissue (tumor grafts) and cells (both untreated and treated)
were harvested, and the protein was isolated using a total pro-
tein extraction kit fromMillipore. Theywere then incubated on
ice for 60min followed bymicrocentrifugation at 10,000 g for
15 min at 4C. Aliquots of 40 g of protein from each sample
were boiled in sample preparation buffer from Invitrogen. The
protein samples were separated on 10% polyacrylamide gels
(Bio-Rad) and transferred to nitrocellulose membranes using
the iBlot system (Invitrogen). After blocking in 5% milk in
TBST (Tris-buffered saline with Tween 20), themembrane was
probed with primary antibody (for the desired protein) over-
night at 4 °C. The membranes were washed three times with
TBST for 10 min, incubated with the appropriate secondary
antibodies, and probed with primary antibodies for the desired
protein. The membranes were incubated overnight at 4Cwith
the primary antibodies followed by incubation with secondary
antibodies for 1 h anddetected by a diaminobenzidine substrate
kit (DAB, Thermo Scientific).
Detection of p53mutations in liver, breast, and colon cancer
tissues
The cDNA was prepared from total RNA isolated from breast,
colon, and liver cancer tissues as shown in Fig. 1b. This cDNAwas
used as a template to amplify the DNA-binding domain of p53 as
follows: Forward primer: 5
-CCTTCCCAGAAAACCTACCA-
GGGCAGC-3
; and Reverse primer: 5
-TTTCTTGCGGAGA-
TTCTCTTCCTCTG-3
 (with an expected amplicon length of
585 bp). The PCR products were gel-purified and subjected to
automated DNA sequencing with ultra-HPLC purification (Stab
Vida, Lisbon, Portugal). Themutations detected in the p53DNA-
binding domain from different tissues are shown in Fig. 1c.
Immunoprecipitation
Cells, both untreated and treated (for 24 h), were washed
with PBS, harvested, and lysed in radioimmune precipitation
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.0% (v/v) Tri-
ton X-100, 0.1% SDS, and 1.0% sodium deoxycholate) by incu-
bating them on ice for 30 min followed by centrifugation at
9200  g for 20 min. The whole-cell lysate (1 mg) was pre-
clearedwith proteinG PLUS-agarose beads and incubatedwith
5 g of anti-mouse p53 WT conformation 1620 and p53 MT
conformation 240 monoclonal antibodies on ice for 2 h. Then
10 l of protein G PLUS-agarose was added to the lysate fol-
lowed by further incubation at 4 °C for 4 h. After washing three
times with Nonidet P-40 buffer (20 mM Tris-HCl, pH 7.4, 100
mMNaCl, 10% (v/v) glycerol, 1.0% (v/v)Nonidet P-40, and 1mM
EDTA) and once with radioimmune precipitation buffer, the
beads were resuspended in the sample buffer, boiled for 5 min,
and loaded on to SDS-PAGE (10% gel). Transfer of proteins to
nitrocellulose membranes was performed using the iBlot sys-
tem (Invitrogen), and the membranes were then stripped and
immunoblotted using anti-p53 (FL-393) polyclonal antibody.
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